Management of hypertension and hypercholesterolaemia in primary care in the Netherlands

Current Medical Research and Opinion

Volumn 21, Issue 6, 2005, Pages 839-848

  Van Wyk, Jacobus T ^a   Picelli, Gino ^b   Dieleman, Jeanne P ^a   Mozaffari, Essy ^c   Kramarz, Piotr ^d   Van Wijk, Marc A M ^a   Van Der Lei, Johan ^a   Sturkenboom, Miriam C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b International Pharmacoepidemiology and Pharmacoeconomics Research Center   (Italy)

^c PFIZER INC   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Hypercholesterolaemia; Hypertension; Patient management; Primary care; Screening; Treatment; Undertreatment

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PRAVASTATIN; SIMVASTATIN; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; COHORT ANALYSIS; CONFERENCE PAPER; EUROPE; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INDUSTRIALIZATION; MAJOR CLINICAL STUDY; MALE; MONITORING; NETHERLANDS; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; SCREENING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CHOLESTEROL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; NETHERLANDS; PRACTICE GUIDELINES; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 21244441547     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X46368     Document Type: Conference Paper

References (42)

1. World Health Organization. The World Health Report 2003. Shaping the Future. Geneva: World Health Organization, 2003
2. Thomas F, Bean K, Guize L, et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (< 55 years) men and women. Eur Heart J 2002;23:528-35
3. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35
4. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 2000;321:938-6
5. Klungel OH, de Boer A, Paes AH, et al. Undertreatment of hypertension in a population-based study in The Netherlands. J Hypertens 1998;16:1371-8
6. Klungel OH, Stricker BH, Paes AH, et al. Excess stroke among hypertensive men and women attributable to Undertreatment of hypertension. Stroke 1999;30:1312-8
7. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357:995-1001
8. Boersma E, Keil U, De Bacquer D, et al. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 2003;21:1831-40
9. Bottorff MB. Underidentification and undertreatment issues. J Manag Care Pharm 2003;9(Suppl):6-8
10. Devrcey D, Betz W, Kartounian J. An evaluation of pharmaceutical treatment of dyslipidaemia among patients without diagnosed atherosclerotic disease in Belgium. Int J Clin Pract 2003;57:720-5
11. Mantel-Teeuwisse AK, Verschuren WM, Klungel OH, et al. Undertreatment of hypercholesterolaemia: a population-based study. Br J Clin Pharmacol 2003;55:389-97
12. Wright DJ, Grayson AD, Jackson M, et al. The reality of treating dyslipidaemia in patients with coronary heart disease: a primary care survey. Int J Clin Pract 2003;57:488-91
13. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-7.
14. Schelleman H, Klungel OH, Kromhout D, et al. Prevalence and determinants of undertreatment of hypertension in the Netherlands. J Hum Hypertens 2004;18:317-24
15. Mantel-Teeuwisse AK. Quality and safety aspects of lipid-lowering drug use. Utrecht: University of Utrecht; 2004
16. Geijer R, Burger J, Van der Laan J, et al. NHG-standaarden voor de huisarts. In: Maarsen: Elsevier/Bunge; 1999, pp. 187-205
17. Thomas S, Van der Wijden T, et al. NHG-Standaard Cholesterol. Huisarts en Wetenschap 1999;42:406-17
18. Walma E, Thomas S, Prins A, et al. NHG-standaard Hypertensie (NHG standard hypertension). Huisarts en Wetenschap 2003;46:435-49
19. Van der Lei J, Duisterhout JS, Westerhof HP, et al. The introduction of computer-based patient records in The Netherlands. Ann Intern Med 1993;119:1036-41
20. Vlug AE, van der Lei J, Mosseveld BM, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999;38:339-44
21. Lamberts H, Wood M. International Classification of Primary Care. Oxford: Oxford University Press, 1987
22. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8
23. Vliet AL, Van den Hof S, Elvers LH, et al. Risicofactoren En Gezondheids Evaluatie Nederlandse Bevolking, een Onderzoek op GGD'en, jaarverslag 2001. Bilthoven: RIVM, 2001. Report No: 260854004/2003
24. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151-83
25. Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care 2001;39(Suppl 2):1146-54
26. Grol R, Dalhuijsen J, Thomas S, et al. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. BMJ 1998;317:858-61
27. Cabana MD, Rand CS, Powe NR, et al. Why don't physician's follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458-65
28. McAlister FA, Campbell NR, Zarnke K, et al. The management of hypertension in Canada: a review of current guidelines, their shortcomings and implications for the future. CMAJ 2001;164:517-22
29. Kedward J, Dakin L. A qualitative study of barriers to the use of statins and implementation of coronary heart disease prevention in primary care. Br J Gen Pract 2003;53:684-9
30. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997;18:1569-82
31. Lemaitre RN, Furberg CD, Newmann AB, et al. Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study. Arch Intern Med 1998;158:1761-8
32. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000;321:1322-5
33. Abookire SA, Karson AS, Fiskio J, et al. Use and monitoring of 'statin' lipid-lowering drugs compared with guidelines. Arch Intern Med 2001;161:53-8
34. van Dam M, van Wissen S, Kastelein JJ. Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterol. J Cardiovasc Risk 2002;9:89-95
35. Vale MJ, Jelinek MV, Best JD; COACH study group. Coaching patients on Achieving Cardiovascular Health. How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000. Med J Aust 2002;176:211-5
36. Heidrich J, Liese AD, Kalic M, et al. [Secondary prevention of coronary heart disease. Results from EuroASPIRE I and II in the region of Munster, Germany] [Article in German]. Dtsch Med Wochenschr 2002;127:667-72
37. Natarajan S, Nietert PJ. National trends in screening, prevalence, and treatment of cardiovascular risk factors. Prev Med 2003;36:389-97
38. de Lusignan S, Dzregah B, Hague N, et al. Cholesterol management in patients with IHD: an audit-based appraisal of progress towards clinical targets in primary care. Br J Cardiol 2003;10:223-8
39. Pyörälä K, Lehto S, De Bacquer D, et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys. Diabetologia 2004;47:1257-65
40. Primatesta P, Poulter NR. Lipid levels and the use of lipid-lowering agents in England and Scotland. Eur J Cardiovasc Prev Rehabil 2004;11:484-8
41. Primatesta P, Poulter NR. Hypertension management and control among English adults aged 65 years and older in 2000 and 2001. J Hypertens 2004;22:1093-8
42. Ornstein SM, Nietert PJ, Dickerson LM. Hypertension management and control in primary care: a study of 20 practices in 14 states. Pharmacotherapy 2004;24:500-7